Your browser doesn't support javascript.
loading
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030.
Guzzinati, S; Toffolutti, F; Francisci, S; De Paoli, A; Giudici, F; De Angelis, R; Demuru, E; Botta, L; Tavilla, A; Gatta, G; Capocaccia, R; Zorzi, M; Caldarella, A; Bidoli, E; Falcini, F; Bruni, R; Migliore, E; Puppo, A; Ferrante, M; Gasparotti, C; Gambino, M L; Carrozzi, G; Bianconi, F; Musolino, A; Cavallo, R; Mazzucco, W; Fusco, M; Ballotari, P; Sampietro, G; Ferretti, S; Mangone, L; Mantovani, W; Mian, M; Cascone, G; Manzoni, F; Galasso, R; Piras, D; Pesce, M T; Bella, F; Seghini, P; Fanetti, A C; Pinna, P; Serraino, D; Rossi, S; Dal Maso, L.
Afiliação
  • Guzzinati S; Veneto Tumour Registry, Epidemiological Department, Azienda Zero, Padova. Electronic address: stefano.guzzinati@azero.veneto.it.
  • Toffolutti F; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano.
  • Francisci S; National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome.
  • De Paoli A; Veneto Tumour Registry, Epidemiological Department, Azienda Zero, Padova.
  • Giudici F; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano.
  • De Angelis R; Department of Oncology and Molecular Medicine, National Institute of Health, Rome.
  • Demuru E; Department of Oncology and Molecular Medicine, National Institute of Health, Rome.
  • Botta L; Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Tavilla A; National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome.
  • Gatta G; Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Capocaccia R; Epidemiologia & Prevenzione Editorial Board, Milan.
  • Zorzi M; Veneto Tumour Registry, Epidemiological Department, Azienda Zero, Padova.
  • Caldarella A; Tuscany Cancer Registry, Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence.
  • Bidoli E; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano.
  • Falcini F; Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Forlì.
  • Bruni R; Coordination Centre of the Cancer Registry of Puglia - Strategic Regional Agency for Health and Social Care (AReSS), Bari.
  • Migliore E; Piedmont Cancer Registry, CPO Piemonte and University of Turin, Turin.
  • Puppo A; Liguria Cancer Registry, IRCCS Ospedale Policlinico San Martino, Genova.
  • Ferrante M; Registro Tumori Integrato di Catania-Messina-Enna, UOC Igiene Ospedaliera, Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco, Catania.
  • Gasparotti C; ATS Brescia Cancer Registry, Struttura Semplice di Epidemiologia, Brescia.
  • Gambino ML; Registro Tumori ATS Insubria (Provincia di Como e Varese) Responsabile S.S. Epidemiologia Registri Specializzati e Reti di Patologia, Varese.
  • Carrozzi G; Emilia-Romagna Cancer Registry, Modena Unit, Public Health Department, Local Health Authority, Modena.
  • Bianconi F; Umbria Cancer Registry, PuntoZero Scarl, Perugia.
  • Musolino A; Emilia-Romagna Cancer Registry, Parma Unit, Medical Oncology Unit, University Hospital of Parma, Parma.
  • Cavallo R; Registro Tumori ASL Salerno-Dipartimento di Prevenzione, Salerno.
  • Mazzucco W; Clinical epidemiology and Cancer Registry Unit, Azienda Ospedaliera Universitaria Policlinico (AOUP) di Palermo, Palermo.
  • Fusco M; UOSD Registro Tumori ASL Napoli 3 Sud, Napoli.
  • Ballotari P; SC Osservatorio Epidemiologico, ATS Val Padana, Mantova.
  • Sampietro G; Bergamo Cancer Registry, Epidemiological Service, Agenzia di Tutela della Salute, Bergamo.
  • Ferretti S; Emilia-Romagna Cancer Registry, Ferrara Unit, Local Health Authority, Ferrara; University of Ferrara, Ferrara.
  • Mangone L; Emilia-Romagna Cancer Registry, Reggio Emilia Unit, Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia.
  • Mantovani W; Trento Province Cancer Registry, Clinical and Evaluative Epidemiology Unit, Local Health Authority, Trento.
  • Mian M; Innovation, Research and Teaching Service (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU); College of Health Care-Professions Claudiana, Bolzano-Bozen.
  • Cascone G; Azienda Sanitaria Provinciale Ragusa - UOSD Registro Tumori, Ragusa.
  • Manzoni F; Cancer Registry of the Province of Pavia - Epidemiology Unit - Health Protection Agency of Pavia, Pavia.
  • Galasso R; Unit of Regional Cancer Registry, Clinical Epidemiology and Biostatistics, IRCCS CROB, Rionero in Vulture (PZ).
  • Piras D; Nord Sardegna Cancer Registry, ASL Sassari, Sassari.
  • Pesce MT; Monitoraggio rischio ambientale e Registro Tumori ASL Caserta, Caserta.
  • Bella F; Siracusa Cancer Registry, Provincial Health Authority of Siracusa, Siracusa.
  • Seghini P; Emilia-Romagna Cancer Registry, Piacenza Unit, Unit of Epidemiology AUSL Piacenza, Piacenza.
  • Fanetti AC; Agenzia di Tutela della Salute della Montagna Cancer Registry, Sondrio.
  • Pinna P; Nuoro Cancer Registry, ASL Nuoro, Nuoro, Italy.
  • Serraino D; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano.
  • Rossi S; Department of Oncology and Molecular Medicine, National Institute of Health, Rome.
  • Dal Maso L; Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano. Electronic address: dalmaso@cro.it.
ESMO Open ; 9(7): 103635, 2024 Jul 22.
Article em En | MEDLINE | ID: mdl-39043021
ABSTRACT

BACKGROUND:

The number and projections of cancer survivors are necessary to meet the healthcare needs of patients, while data on cure prevalence, that is, the percentage of patients who will not die of cancer by time since diagnosis, are lacking. MATERIALS AND

METHODS:

Data from Italian cancer registries (duration of registration ranged from 9 to 40 years, with a median of 22 years) covering 47% of the population were used to calculate the limited-duration prevalence, the complete prevalence in 2018, projections to 2030, and cure prevalence, by cancer type, sex, age, and time since diagnosis.

RESULTS:

A total of 3 347 809 people were alive in Italy in 2018 after a cancer diagnosis, corresponding to 5.6% of the resident population. They will increase by 1.5% per year to 4 012 376 in 2030, corresponding to 6.9% of the resident population, 7.6% of women and ∼22% after age 75 years. In 2030, more than one-half of all prevalent cases (2 million) will have been diagnosed by ≥10 years. Those with breast (1.05 million), prostate (0.56 million), or colorectal cancers (0.47 million) will be 52% of all prevalent patients. Cure prevalence was 86% for all patients alive in 2018 (87% for patients with breast cancer and 99% for patients with thyroid or testicular cancer), increasing with time since diagnosis to 93% for patients alive after 5 years and 96% after 10 years. Among patients who survived at least 5 years, the excess risk of death (1 - cure prevalence) was <5% for patients with most cancer types except for those with cancers of the breast (8.3%), lung (11.1%), kidney (13.2%), and bladder (15.5%).

CONCLUSIONS:

Study findings encourage the implementation of evidence-based policies aimed at improving long-term clinical follow-up and rehabilitation of people living after cancer diagnosis throughout the course of the disease. Updated estimates of complete prevalence are important to enhance data-driven cancer control planning.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article